Biomarin Pharmaceutical (BMRN) Net Income towards Common Stockholders (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Net Income towards Common Stockholders data on file, last reported at $105.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 43.17% year-over-year to $105.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.7 million (down 48.7% YoY) and the FY2025 annual result came in at $348.9 million, down 18.26% from the prior year.
• Net Income towards Common Stockholders improved to $105.5 million in Q1 2026, from -$46.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $240.5 million in Q2 2025 to a low of -$46.6 million in Q4 2025.
• A 5-year average of $70.0 million and a median of $56.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 8282.73% — and 2025, when it slumped 137.28%.
• Tracing BMRN's Net Income towards Common Stockholders over 5 years: stood at -$249000.0 in 2022, then soared by 8282.73% to $20.4 million in 2023, then jumped by 513.22% to $124.9 million in 2024, then tumbled by 137.28% to -$46.6 million in 2025, then soared by 326.58% to $105.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $105.5 million (Q1 2026), -$46.6 million (Q4 2025), and -$30.7 million (Q3 2025), per Business Quant data.